137 related articles for article (PubMed ID: 38791921)
1. Longitudinal Evaluation of DCE-MRI as an Early Indicator of Progression after Standard Therapy in Glioblastoma.
Arevalo-Perez J; Trang A; Yllera-Contreras E; Yildirim O; Saha A; Young R; Lyo J; Peck KK; Holodny AI
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791921
[No Abstract] [Full Text] [Related]
2. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery.
Chidambaram S; Pannullo SC; Roytman M; Pisapia DJ; Liechty B; Magge RS; Ramakrishna R; Stieg PE; Schwartz TH; Ivanidze J
Neurosurg Focus; 2019 Jun; 46(6):E10. PubMed ID: 31153141
[TBL] [Abstract][Full Text] [Related]
4. Dependence of DCE-MRI biomarker values on analysis algorithm.
Ng CS; Wei W; Bankson JA; Ravoori MK; Han L; Brammer DW; Klumpp S; Waterton JC; Jackson EF
PLoS One; 2015; 10(7):e0130168. PubMed ID: 26208254
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
[TBL] [Abstract][Full Text] [Related]
7. T1-weighted Dynamic Contrast-enhanced MRI to Differentiate Nonneoplastic and Malignant Vertebral Body Lesions in the Spine.
Guan Y; Peck KK; Lyo J; Tisnado J; Lis E; Arevalo-Perez J; Yamada Y; Hameed MR; Karimi S; Holodny A
Radiology; 2020 Nov; 297(2):382-389. PubMed ID: 32870135
[TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy.
Lis E; Saha A; Peck KK; Zatcky J; Zelefsky MJ; Yamada Y; Holodny AI; Bilsky MH; Karimi S
Neurosurg Focus; 2017 Jan; 42(1):E9. PubMed ID: 28041318
[TBL] [Abstract][Full Text] [Related]
9. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy.
Chu S; Karimi S; Peck KK; Yamada Y; Lis E; Lyo J; Bilsky M; Holodny AI
Spine (Phila Pa 1976); 2013 Oct; 38(22):E1418-24. PubMed ID: 23873238
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced magnetic resonance imaging parameter changes as an early biomarker of tumor responses following radiation therapy in patients with spinal metastases: a systematic review.
Mulyadi R; Putri PP; Handoko H; Zairinal RA; Prihartono J
Radiat Oncol J; 2023 Dec; 41(4):225-236. PubMed ID: 38185927
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
O'Neill AF; Qin L; Wen PY; de Groot JF; Van den Abbeele AD; Yap JT
J Neurooncol; 2016 Dec; 130(3):495-503. PubMed ID: 27576699
[TBL] [Abstract][Full Text] [Related]
13. Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases.
Spratt DE; Arevalo-Perez J; Leeman JE; Gerber NK; Folkert M; Taunk NK; Alektiar KM; Karimi S; Lyo JK; Tap WD; Bilsky MH; Laufer I; Yamada Y; Osborne JR
Spine J; 2016 Mar; 16(3):291-8. PubMed ID: 26325017
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
[TBL] [Abstract][Full Text] [Related]
15. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
[TBL] [Abstract][Full Text] [Related]
16. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
17. Quantitative subchondral bone perfusion imaging in knee osteoarthritis using dynamic contrast enhanced MRI.
de Vries BA; van der Heijden RA; Verschueren J; Bos PK; Poot DHJ; van Tiel J; Kotek G; Krestin GP; Oei EHG
Semin Arthritis Rheum; 2020 Apr; 50(2):177-182. PubMed ID: 31427104
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
[TBL] [Abstract][Full Text] [Related]
19. Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma.
Woodall RT; Sahoo P; Cui Y; Chen BT; Shiroishi MS; Lavini C; Frankel P; Gutova M; Brown CE; Munson JM; Rockne RC
Neurooncol Adv; 2021; 3(1):vdab174. PubMed ID: 34988454
[TBL] [Abstract][Full Text] [Related]
20. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Schmainda KM; Prah MA; Marques H; Kim E; Barboriak DP; Boxerman JL
Neuro Oncol; 2021 Feb; 23(2):314-323. PubMed ID: 32678438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
